Literature DB >> 19478078

S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis.

Jian Hua Qi1, Ganying Dai, Philip Luthert, Shyam Chaurasia, Joe Hollyfield, Bernhard H F Weber, Heidi Stöhr, Bela Anand-Apte.   

Abstract

Tissue Inhibitor of metalloproteinases-3 (TIMP-3) is a potent matrix-bound angiogenesis inhibitor. Mutations in TIMP-3 cause Sorsby Fundus Dystrophy, a dominant inherited, early onset macular degenerative disease, with choroidal neovascularization causing a loss of vision in the majority of patients. Here we report that expression of S156C TIMP-3 mutation in endothelial cells results in an abnormal localization of the protein, increased glycosylation, decreased matrix metalloproteinase inhibitory activity, and increased vascular endothelial growth factor (VEGF) binding with a consequent increase in VEGF-dependent migration and tube formation. These enhanced signaling events appear to be mediated as a consequence of a post-transcriptionally regulated increase in the expression of membrane-associated VEGFR-2 in endothelial cells of Timp-3(156/156) mutant mice as well as in human Sorsby fundus dystrophy eyes. Understanding the mechanism(s) by which mutant TIMP-3 can induce abnormal neovascularization provides important insight into the pathophysiology of a number of diseases with increased angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478078      PMCID: PMC2740418          DOI: 10.1074/jbc.M109.013763

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications.

Authors:  F Mannello; G Gazzanelli
Journal:  Apoptosis       Date:  2001-12       Impact factor: 4.677

2.  Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity.

Authors:  M Bond; G Murphy; M R Bennett; A Amour; V Knauper; A C Newby; A H Baker
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

3.  Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis.

Authors:  Jian Hua Qi; Quteba Ebrahem; Karen Yeow; Dylan R Edwards; Paul L Fox; Bela Anand-Apte
Journal:  J Biol Chem       Date:  2002-01-30       Impact factor: 5.157

4.  Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors.

Authors:  Matti Ahonen; Minna Poukkula; Andrew H Baker; Masahide Kashiwagi; Hideaki Nagase; John E Eriksson; Veli-Matti Kähäri
Journal:  Oncogene       Date:  2003-04-10       Impact factor: 9.867

5.  A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy.

Authors:  K P Langton; N McKie; A Curtis; J A Goodship; P M Bond; M D Barker; M Clarke
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

6.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.

Authors:  Louise E Reynolds; Lorenza Wyder; Julie C Lively; Daniela Taverna; Stephen D Robinson; Xiaozhu Huang; Dean Sheppard; Richard O Hynes; Kairbaan M Hodivala-Dilke
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

7.  Sorsby's fundus dystrophy mutant tissue inhibitors of metalloproteinase-3 induce apoptosis of retinal pigment epithelial and MCF-7 cells.

Authors:  Mohammed A Majid; Valerie A Smith; David L Easty; Andrew H Baker; Andrew C Newby
Journal:  FEBS Lett       Date:  2002-10-09       Impact factor: 4.124

8.  A mouse model for Sorsby fundus dystrophy.

Authors:  Bernhard H F Weber; Biaoyang Lin; Karen White; Konrad Kohler; Galina Soboleva; Sabine Herterich; Mathias W Seeliger; Gesine B Jaissle; Christian Grimm; Charlotte Reme; Andreas Wenzel; Esther Asan; Heinrich Schrewe
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-08       Impact factor: 4.799

9.  Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol.

Authors:  Lyne Labrecque; Isabelle Royal; David S Surprenant; Cam Patterson; Denis Gingras; Richard Béliveau
Journal:  Mol Biol Cell       Date:  2003-01       Impact factor: 4.138

10.  A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2.

Authors:  Jian Hua Qi; Quteba Ebrahem; Nina Moore; Gillian Murphy; Lena Claesson-Welsh; Mark Bond; Andrew Baker; Bela Anand-Apte
Journal:  Nat Med       Date:  2003-03-24       Impact factor: 53.440

View more
  24 in total

Review 1.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

2.  Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury.

Authors:  Claudia Schrimpf; Cuiyan Xin; Gabriella Campanholle; Sean E Gill; William Stallcup; Shuei-Liong Lin; George E Davis; Sina A Gharib; Benjamin D Humphreys; Jeremy S Duffield
Journal:  J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 10.121

3.  Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).

Authors:  Benjamin M Neale; Jesen Fagerness; Robyn Reynolds; Lucia Sobrin; Margaret Parker; Soumya Raychaudhuri; Perciliz L Tan; Edwin C Oh; Joanna E Merriam; Eric Souied; Paul S Bernstein; Binxing Li; Jeanne M Frederick; Kang Zhang; Milam A Brantley; Aaron Y Lee; Donald J Zack; Betsy Campochiaro; Peter Campochiaro; Stephan Ripke; R Theodore Smith; Gaetano R Barile; Nicholas Katsanis; Rando Allikmets; Mark J Daly; Johanna M Seddon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Drusen in patient-derived hiPSC-RPE models of macular dystrophies.

Authors:  Chad A Galloway; Sonal Dalvi; Sandy S C Hung; Leslie A MacDonald; Lisa R Latchney; Raymond C B Wong; Robyn H Guymer; David A Mackey; David S Williams; Mina M Chung; David M Gamm; Alice Pébay; Alex W Hewitt; Ruchira Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-06       Impact factor: 11.205

5.  Integrin α7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells.

Authors:  Lang-Zhu Tan; Yang Song; Joel Nelson; Yan P Yu; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2013-07-02       Impact factor: 4.307

6.  Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism.

Authors:  Jian Hua Qi; Bela Anand-Apte
Journal:  Apoptosis       Date:  2015-04       Impact factor: 4.677

Review 7.  Sorsby fundus dystrophy: Insights from the past and looking to the future.

Authors:  Bela Anand-Apte; Jennifer R Chao; Ruchira Singh; Heidi Stöhr
Journal:  J Neurosci Res       Date:  2018-08-21       Impact factor: 4.164

8.  Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization.

Authors:  Juan Amaral; S Patricia Becerra
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

9.  Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization.

Authors:  Gandra Mamatha; Vetrivel Umashankar; Nachiappan Kasinathan; Tandava Krishnan; Ravichandran Sathyabaarathi; Thirumalai Karthiyayini; John Amali; Chetan Rao; Jagadeesan Madhavan
Journal:  Mol Vis       Date:  2011-07-20       Impact factor: 2.367

10.  Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

Authors:  Jian Hua Qi; Quteba Ebrahem; Mariya Ali; Alecia Cutler; Brent Bell; Nicholas Prayson; Jonathan Sears; Vera Knauper; Gillian Murphy; Bela Anand-Apte
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.